Efimosfermin alfa for alcohol-related liver disease
Treatments studied
Part of Digestive system clinical trials.
This study tests an investigational medicine called efimosfermin alfa to see if it is safe and effective for people with liver damage caused by heavy drinking. The medicine is compared to a placebo (a dummy treatment).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a history of heavy alcohol use for more than 6 months at some point in your life.
- You do not have other major causes of liver disease (like viral hepatitis or autoimmune hepatitis).
- You do not have diabetes or if you do, it is well-controlled without major complications.
- You have not been treated with a similar medicine (e.g., resmetirom or an FGF21 analogue) in the past 3 to 6 months.
- You are willing to use effective contraception if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
This trial tests a program to help people recently diagnosed with alcohol-related liver disease cut back on drinking. If you qualify, you may get support to improve your liver health.
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Hear when a new Liver Diseases, Alcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.